Fetal vs Perinatal EVs as potential OA Therapeutics
Fetal vs Perinatal EVs as potential OA Therapeutics September 2nd, 2025, Vienna, Austria We are pleased to share a new publication
2
09, 2025
10
03, 2025
New Cell Systems developed in collaboration with AIM Biotech
New Cell Systems developed in collaboration with AIM Biotech March 10th, 2025, Vienna, Austria Two innovative 3D assay kits for advanced
26
11, 2024
Recently published article on Cyclosporin A toxicity on endothelial cell
Recently published article on the mechanistic toxicology of Cyclosporin A and its effects on angiogenesis November 26th, 2024, Vienna, Austria A recent
4
11, 2024
Recently published article on generating endothelial and vascular smooth muscle cells from PBMC and urine-derived iPSCs
Recently published article on generating endothelial and vascular smooth muscle cells from PBMC and urine-derived iPSCs November 4th, 2024, Vienna, Austria
4
11, 2024
Partnering with AIM Biotech
Partnering with AIM Biotech November 4th, 2024, Vienna, Austria We are thrilled to announce that we have partnered with Singapore-based AIM
5
09, 2024
Review on fetal-maternal interactions by LifeSaver Project Consortium
New review published by LifeSaver Project Consortium September 5th, 2024, Vienna, Austria The LifeSaver Project Consortium has published a comprehensive review
22
11, 2023
Evercyte Showcases Expertise in Japan’s Pharma Landscape
Evercyte Showcases Expertise in Japan’s Pharma Landscape November 22nd, 2023, Vienna, Austria We recently visited Summit Pharmaceuticals International to present our
4
08, 2023
RPTEC/TERT1 relevant kidney-on-a-chip model
Collaboration with Nortis to establish human kidney-on-a-chip model August 4th, 2023. Vienna, Austria Our telomerized Human Renal Proximal Tubular Epithelial cells (RPTEC/TERT1) were used in collaboration with